ABOUT US
30 years of expertise in product development
00:00:02.944 --> 00:00:06.480
Jonathan Rubin: When you bring a drug to market, you have
00:00:06.480 --> 00:00:11.761
the potential to affect the lives of many, many people and their families.
00:00:11.761 --> 00:00:16.803
Rebecca Lannan: The impact that our eight marketed products have on patients' lives is significant.
00:00:16.803 --> 00:00:22.560
We cross between migraine prevention, to epilepsy, to Parkinson's disease, and now
00:00:22.560 --> 00:00:28.199
onto ADHD, with our launch product Qelbree. Those patients' lives, across
00:00:28.199 --> 00:00:31.028
children and adults, are changed forever from our products.
00:00:32.029 --> 00:00:36.032
Chad Tasker: What makes us so competitive is we put our patients first; everything we do is dedicated to make
00:00:36.032 --> 00:00:39.452
our patients' lives better. Customer service is number one, we eat sleep and
00:00:39.452 --> 00:00:43.039
breathe that every day——and we live up to it, and it shows each and every day in
00:00:43.039 --> 00:00:44.039
our deliveries.
00:00:44.873 --> 00:00:46.041
Sarah Munoz: Something that really stands out is the
00:00:46.041 --> 00:00:49.780
fact that we are able to help and change so many lives.
00:00:49.780 --> 00:00:54.924
I will never forget the experience of going into a doctor's office, talking to a doctor about our products,
00:00:54.924 --> 00:01:00.214
and being able to hear about their patients whose lives were benefited from our drugs.
00:01:00.846 --> 00:01:04.558
Bryan Roecklein: What one of the greatest aspects of Supernus is that we have a number of products on
00:01:04.558 --> 00:01:06.426
the marketplace generating revenue.
00:01:06.426 --> 00:01:09.911
We have a late-stage product under FDA review.
00:01:10.021 --> 00:01:13.023
We have two mid-stage products that are entering the clinic soon.
00:01:13.649 --> 00:01:17.048
And then we also have an early-stage discovery platform;
00:01:17.048 --> 00:01:20.655
so Supernus is not only growing, but it's going to be growing for a long time.
00:01:20.655 --> 00:01:25.055
Konnie Taylor: We are able to bring so many products to the market because of the people, because of the
00:01:25.055 --> 00:01:30.420
culture, and all of the hard work that everyone puts in——with the end goal of helping the patient.
00:01:30.420 --> 00:01:34.042
Roy Thomas: The number one differentiator is the culture that we've created.
00:01:34.042 --> 00:01:37.880
Erin Agustinus: Whether marketing, whether finance, all the way up to our CEO Jack.
00:01:37.880 --> 00:01:42.240
Logan Hoffman: Every day excited to come in just because of the people——you know, everyone around from senior
00:01:42.240 --> 00:01:47.053
leadership, down to our reps——we're 100% about our people. Everyone's excited to
00:01:47.053 --> 00:01:49.931
be here, coming in with a positive attitude every single day.
00:01:49.931 --> 00:01:54.659
Frank Mottola: Supernus Pharmaceuticals is more than just a lab—— you can be in the lab, you can be in
00:01:54.659 --> 00:01:58.259
sales, you can be in marketing, you can be in operations, you can be part of the
00:01:58.259 --> 00:02:03.000
management team, you can be part of the executive team, it doesn't matter——we all
00:02:03.000 --> 00:02:08.239
work for the same exact mission: bettering the lives of our patients.
00:02:08.364 --> 00:02:10.241
We ARE SUPERNUS!
SUPERNUS’ STORY
We are a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Over the last 30 years, we have built an extensive expertise in product development. Initially, we were a stand-alone development organization, then a U.S. subsidiary of Shire plc and, in late 2005, we became Supernus Pharmaceuticals, Inc.
Supernus Mission and Values
Mission: To improve the lives of patients suffering from diseases of the central nervous system (CNS)
Values:
Integrity
Commitment
Innovation
Caring
We market our products within the United States through our own specialty sales forces. We also seek strategic collaborations with other pharmaceutical companies to license our products outside the United States.
A record of successful products, with more in development
We market Qelbree® (viloxazine) extended-release capsules for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ages 6 years and older, Trokendi XR® (topiramate) extended-release capsules for the preventive treatment of migraine and the treatment of certain types of epilepsy, Oxtellar XR® (oxcarbazepine) extended-release tablets for the treatment of partial onset seizures, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD) and GOCOVRI® (amantadine) extended release capsules for the treatment of both OFF and dyskinesia in patients with Parkinson’s disease (PD).
Additionally, we market Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility and Osmolex ER® (amantadine) extended release tablets for the treatment of Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients.
A record of successful products, with more in development:
SPN-830 for hypomobility in Parkinson’s disease »
SPN-820 (NV-5138) for treatment-resistant depression »
SPN-817 for the treatment of certain types of epilepsy »
Please see important product specific information here.
Please see important product-specific information here.
Shaping the future by focusing on novel treatments
At Supernus, we strive to be a leader in the CNS industry by developing and commercializing new medicines in neurology and psychiatry. Some key elements of our strategy to accomplish this vision are to:
Drive growth and profitability.
Using dedicated sales and marketing resources in the U.S., we will continue to drive the revenue growth of Qelbree®, Trokendi XR®, Oxtellar XR®, Apokyn®, GOCOVRI®, Xadago®, Myobloc® and Osmolex ER®.
Advance product candidates toward commercialization.
Several product candidates in our pipeline are in early-to-late stage clinical testing, and moving toward being commercially available to patients.
Continue to grow our pipeline.
We will continue to evaluate and develop additional CNS product candidates that we believe have significant commercial potential through our internal research and development efforts.
Target strategic business development opportunities.
We are actively exploring a broad range of strategic opportunities. This includes in-licensing products and entering into co-promotion and co-development partnerships for our marketed products and product candidates.
